Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Brancheau

Podiatrist Greenville, TX Doctor of Podiatric Medicine

NPI 1013373885 CMS profile 4220472

3900 Joe Ramsey Blvd E Bldg 5, Greenville, TX 75401

Open in the dashboard

General payments

$22,613

232 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Brancheau of Greenville, TX is reported in the CMS Open Payments database as having received $22,613 across 232 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,065 47
2024 General $2,203 41
2023 General $1,047 26
2022 General $5,054 31
2021 General $1,252 30
2020 General $2,529 27
2019 General $8,464 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Brancheau
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Paul Brancheau were reported at $2,065. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Paul Brancheau Podiatrist median Middle half National median
2019 $8,464 $196 $72–$601 $163
2020 $2,529 $118 $38–$335 $114
2021 $1,252 $169 $57–$573 $132
2022 $5,054 $220 $74–$782 $149
2023 $1,047 $208 $71–$635 $160
2024 $2,203 $237 $87–$681 $164
2025 $2,065 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. In2Bones USA, LLC $8,449 2 payments
  2. Stryker Corporation $3,983 78 payments
  3. Pylant Medical $3,311 10 payments
  4. Arthrex, Inc. $1,782 17 payments
  5. Smith+Nephew, Inc. $977 34 payments
  6. Integra LifeSciences Corporation $935 14 payments
  7. Wright Medical Technology, Inc. $688 18 payments
  8. PolyNovo North America LLC $234 7 payments
  9. TriMed, Inc. $209 2 payments
  10. Bioventus LLC $208 7 payments
  11. Other $1,836 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,924 219 payments
  2. Travel and Lodging $7,985 6 payments
  3. Education $4,229 5 payments
  4. Consulting Fee $1,200 1 payment
  5. Gift $274 1 payment
Products named General payments · program years 2019–2025
  1. CoLink $1,200 1 payment
  2. Integra Recon-Skin And Wound $861 13 payments
  3. Integra Recon-Skin And Wound $861 13 payments
  4. PRIMATRIX $861 13 payments
  5. Integra Recon-Skin And Wound $861 13 payments
  6. INTEGRA DERMAL REGENERATION TEMPLATE $861 13 payments
  7. INBONE $441 6 payments
  8. AUGMENT INJECTABLE $424 9 payments
  9. PROSTEP $420 4 payments
  10. INFINITY $412 5 payments
  11. Other $8,334 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

750

Median for Podiatry: 160

Drug cost

$8,155

Median for Podiatry: $2,368

Branded share of claims

14.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 88 $1,687
Doxycycline Hyclate Generic 80 $978
Ciclopirox Generic 28 $863
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 83 $843
Gabapentin Generic 76 $690
Terbinafine Hcl Generic 79 $686
Ciprofloxacin Hcl Generic 51 $580
Methylprednisolone Generic 48 $414
Cephalexin Generic 41 $248
Nystatin-Triamcinolone Nystatin/Triamcinolone Acet Brand 15 $229

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$254,864

Medicare's payments for the services billed

Medicare patients

442

Average age 75

Services billed

1,987

263 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 46%
Chronic kidney disease 33%
Ischemic heart disease 31%
Heart failure 24%
Atrial fibrillation 23%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

232 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record